Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 6:44 p.m.

    📋 NRx Pharmaceuticals Inc (NRXP) - Regulatory Update

    Filing Date: 2026-01-16

    Accepted: 2026-01-16 17:09:24

    Event Type: Regulatory Update

    Event Details:

    NRx Pharmaceuticals Inc (NRXP) Announces Regulatory Update NRx Pharmaceuticals Inc (NRXP) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: • Applications: NDA (New Drug Application) • Designations: Breakthrough Therapy, Fast Track Clinical Development:
    • anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Brian Korb Managing Partner, astr partners (917) 653-5122

    🔬 Clinical Development Pipeline (NRx Pharmaceuticals Inc):

    Product Type Development Stage Therapeutic Area Source
    NRX194204 DRUG Phase PHASE2 Non-small Cell Lung Cancer ClinicalTrials.gov
    NRX 195183 Soft Gelatin Capsule DRUG Phase PHASE2 Acute Promyelocytic Leukemia ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: NRx Pharmaceuticals Inc
    • Ticker Symbol: NRXP

Search

News categories